Epigenetics in myelodysplastic syndromes

Funding Activity

Website
http://purl.org/au-research/grants/nhmrc/GNT1115041

Funding Status
Closed

Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the .

Funded Activity Summary

Myelodysplastic syndromes (MDS) are disorders of blood-forming stem cells characterised by low blood counts and progression to acute leukaemia. Epigenetics refers to changes in gene expression without changing the underlying DNA sequence. More than half of MDS have mutation/s in epigenetic regulators, providing evidence that epigenetics is an important contributor to the disease. The goal of this project is to better understand how epigenetics contribute to MDS and discovery of new therapies.

Funded Activity Details

Start Date: 01-01-2016

End Date: 01-01-2018

Funding Scheme: Postgraduate Scholarships

Funding Amount: $88,766.00

Funder: National Health and Medical Research Council

Research Topics

ANZSRC Field of Research (FoR)

Medical and Health Sciences not elsewhere classified

ANZSRC Socio-Economic Objective (SEO)

There are no SEO codes available for this funding activity

Other Keywords

acute myeloid leukaemia (AML) | epigenetics | gene expression | myelodysplasia | therapeutic agents

Related Links